Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousand...(ir recurrence risk and is set to improve...),Health

ATAC 100-month results summary:

-- After a median follow-up of over 8 years (100 months), compared with

tamoxifen, anastrozole significantly:(1),(2)

-- reduces the risk of all recurrences by 24% (HR 0.76 [0.67-0.87];

p=0.0001)

-- improves disease free survival by 15% (HR 0.85 [0.76-0.94]; p=0.003)

-- reduces the risk of distant metastases (recurrence elsewhere in the

body) by 16% (HR 0.84 [0.72-0.97]; p=0.022)

-- reduces the incidence of contralateral breast cancer (cancer in the

opposite breast) by 40% (OR 0.60 [0.42-0.85]; p=0.004)

-- Prescribing anastrozole from the start means fewer patients have to

be told the devastating news that their breast cancer has

recurred.(1),(2)

Notes to Editors

For more information, to view a presentation of the ATAC 100 data by Professor John Forbes or to download the ATAC 100 publication in The Lancet Oncology, please visit http://www.ATAC100.com

The study will be published early online (00.01 GMT Saturday 15 December) and in the January edition of The Lancet Oncology.

* ATAC: Arimidex, Tamoxifen, Alone or in Combination

** Physicians: medical oncologists, gynaecologists and breast cancer

surgeons

Patients: postmenopausal women diagnosed with early breast cancer in

the past five years and who had undergone breast cancer surgery

Broadcast-quality video

For broadcast-standard video supporting this press release, please visit http://www.thenewsmarket.com/astrazeneca. If you are a first-time user, please take a moment to register. In case you have any questions, please email